nodes	percent_of_prediction	percent_of_DWPC	metapath
Latanoprost—SLCO2B1—Erlotinib—pancreatic cancer	0.575	1	CbGbCtD
Latanoprost—Cystoid macular oedema—Docetaxel—pancreatic cancer	0.0155	0.051	CcSEcCtD
Latanoprost—Macular oedema—Tamoxifen—pancreatic cancer	0.0137	0.0449	CcSEcCtD
Latanoprost—SLCO2B1—Transport of vitamins, nucleosides, and related molecules—SLC29A1—pancreatic cancer	0.00989	0.0827	CbGpPWpGaD
Latanoprost—Uveitis—Erlotinib—pancreatic cancer	0.00945	0.0311	CcSEcCtD
Latanoprost—PTGFR—Small Ligand GPCRs—CNR2—pancreatic cancer	0.00791	0.0662	CbGpPWpGaD
Latanoprost—Periorbital oedema—Sunitinib—pancreatic cancer	0.00723	0.0238	CcSEcCtD
Latanoprost—Scab—Fluorouracil—pancreatic cancer	0.00709	0.0233	CcSEcCtD
Latanoprost—PTGFR—Small Ligand GPCRs—CNR1—pancreatic cancer	0.00568	0.0475	CbGpPWpGaD
Latanoprost—Eyelid oedema—Sunitinib—pancreatic cancer	0.00567	0.0186	CcSEcCtD
Latanoprost—Embolism—Tamoxifen—pancreatic cancer	0.0052	0.0171	CcSEcCtD
Latanoprost—Keratitis—Erlotinib—pancreatic cancer	0.00509	0.0167	CcSEcCtD
Latanoprost—Embolism—Sunitinib—pancreatic cancer	0.00445	0.0146	CcSEcCtD
Latanoprost—Embolism—Irinotecan—pancreatic cancer	0.00367	0.0121	CcSEcCtD
Latanoprost—Blepharitis—Fluorouracil—pancreatic cancer	0.00367	0.0121	CcSEcCtD
Latanoprost—Inflammation—Tamoxifen—pancreatic cancer	0.00344	0.0113	CcSEcCtD
Latanoprost—Inflammation—Erlotinib—pancreatic cancer	0.00341	0.0112	CcSEcCtD
Latanoprost—Lacrimation increased—Sunitinib—pancreatic cancer	0.0031	0.0102	CcSEcCtD
Latanoprost—Dermatitis atopic—Gemcitabine—pancreatic cancer	0.0031	0.0102	CcSEcCtD
Latanoprost—PTGFR—GPCRs, Other—SSTR2—pancreatic cancer	0.00309	0.0258	CbGpPWpGaD
Latanoprost—Dry eye—Erlotinib—pancreatic cancer	0.00305	0.01	CcSEcCtD
Latanoprost—PTGFR—GPCRs, Other—CCKBR—pancreatic cancer	0.00298	0.0249	CbGpPWpGaD
Latanoprost—Stinging—Fluorouracil—pancreatic cancer	0.00278	0.00915	CcSEcCtD
Latanoprost—Hepatic function abnormal—Tamoxifen—pancreatic cancer	0.00277	0.00911	CcSEcCtD
Latanoprost—Eye irritation—Fluorouracil—pancreatic cancer	0.00264	0.00868	CcSEcCtD
Latanoprost—Lacrimation increased—Irinotecan—pancreatic cancer	0.00256	0.0084	CcSEcCtD
Latanoprost—Embolism—Docetaxel—pancreatic cancer	0.00254	0.00833	CcSEcCtD
Latanoprost—Lacrimation increased—Fluorouracil—pancreatic cancer	0.00245	0.00804	CcSEcCtD
Latanoprost—Hepatic function abnormal—Sunitinib—pancreatic cancer	0.00238	0.0078	CcSEcCtD
Latanoprost—Inflammation—Fluorouracil—pancreatic cancer	0.00233	0.00764	CcSEcCtD
Latanoprost—Eczema—Sunitinib—pancreatic cancer	0.00231	0.00759	CcSEcCtD
Latanoprost—Dermatitis atopic—Docetaxel—pancreatic cancer	0.0022	0.00723	CcSEcCtD
Latanoprost—Toxic epidermal necrolysis—Erlotinib—pancreatic cancer	0.00216	0.0071	CcSEcCtD
Latanoprost—SLCO2B1—SLC-mediated transmembrane transport—SLC29A1—pancreatic cancer	0.00212	0.0178	CbGpPWpGaD
Latanoprost—Photophobia—Fluorouracil—pancreatic cancer	0.00212	0.00696	CcSEcCtD
Latanoprost—Angina pectoris—Tamoxifen—pancreatic cancer	0.00204	0.0067	CcSEcCtD
Latanoprost—Bronchitis—Tamoxifen—pancreatic cancer	0.00201	0.00662	CcSEcCtD
Latanoprost—Eye irritation—Docetaxel—pancreatic cancer	0.00191	0.00627	CcSEcCtD
Latanoprost—Hepatic function abnormal—Gemcitabine—pancreatic cancer	0.00191	0.00626	CcSEcCtD
Latanoprost—Toxic epidermal necrolysis—Sunitinib—pancreatic cancer	0.00187	0.00614	CcSEcCtD
Latanoprost—Urinary tract infection—Tamoxifen—pancreatic cancer	0.00182	0.00597	CcSEcCtD
Latanoprost—Conjunctivitis—Erlotinib—pancreatic cancer	0.0018	0.0059	CcSEcCtD
Latanoprost—Lacrimation increased—Docetaxel—pancreatic cancer	0.00177	0.00581	CcSEcCtD
Latanoprost—Bronchitis—Sunitinib—pancreatic cancer	0.00173	0.00567	CcSEcCtD
Latanoprost—PTGFR—Prostaglandin Synthesis and Regulation—PTGS2—pancreatic cancer	0.00171	0.0143	CbGpPWpGaD
Latanoprost—Embolism—Epirubicin—pancreatic cancer	0.00171	0.00562	CcSEcCtD
Latanoprost—PTGFR—GPCRs, Class A Rhodopsin-like—PRLHR—pancreatic cancer	0.00171	0.0143	CbGpPWpGaD
Latanoprost—Keratitis—Epirubicin—pancreatic cancer	0.00169	0.00556	CcSEcCtD
Latanoprost—Inflammation—Docetaxel—pancreatic cancer	0.00168	0.00552	CcSEcCtD
Latanoprost—PTGFR—G alpha (q) signalling events—CCKBR—pancreatic cancer	0.00167	0.014	CbGpPWpGaD
Latanoprost—Upper respiratory tract infection—Sunitinib—pancreatic cancer	0.00167	0.00548	CcSEcCtD
Latanoprost—Connective tissue disorder—Erlotinib—pancreatic cancer	0.00163	0.00536	CcSEcCtD
Latanoprost—PTGFR—GPCRs, Other—CNR1—pancreatic cancer	0.00162	0.0136	CbGpPWpGaD
Latanoprost—Embolism—Doxorubicin—pancreatic cancer	0.00158	0.0052	CcSEcCtD
Latanoprost—Keratitis—Doxorubicin—pancreatic cancer	0.00157	0.00515	CcSEcCtD
Latanoprost—Urinary tract infection—Sunitinib—pancreatic cancer	0.00155	0.00511	CcSEcCtD
Latanoprost—Toxic epidermal necrolysis—Gemcitabine—pancreatic cancer	0.0015	0.00493	CcSEcCtD
Latanoprost—PTGFR—Gastrin-CREB signalling pathway via PKC and MAPK—CCKBR—pancreatic cancer	0.0015	0.0125	CbGpPWpGaD
Latanoprost—Mediastinal disorder—Erlotinib—pancreatic cancer	0.00149	0.00491	CcSEcCtD
Latanoprost—Dermatitis atopic—Epirubicin—pancreatic cancer	0.00148	0.00488	CcSEcCtD
Latanoprost—PTGFR—Class A/1 (Rhodopsin-like receptors)—PRLHR—pancreatic cancer	0.00146	0.0122	CbGpPWpGaD
Latanoprost—Erythema—Tamoxifen—pancreatic cancer	0.00146	0.0048	CcSEcCtD
Latanoprost—PTGFR—GPCRs, Class A Rhodopsin-like—SSTR3—pancreatic cancer	0.00145	0.0122	CbGpPWpGaD
Latanoprost—Erythema—Erlotinib—pancreatic cancer	0.00144	0.00474	CcSEcCtD
Latanoprost—PTGFR—G alpha (q) signalling events—GAST—pancreatic cancer	0.00144	0.0121	CbGpPWpGaD
Latanoprost—Angina pectoris—Irinotecan—pancreatic cancer	0.00144	0.00473	CcSEcCtD
Latanoprost—Back pain—Tamoxifen—pancreatic cancer	0.00141	0.00464	CcSEcCtD
Latanoprost—Connective tissue disorder—Sunitinib—pancreatic cancer	0.00141	0.00464	CcSEcCtD
Latanoprost—Back pain—Erlotinib—pancreatic cancer	0.0014	0.00459	CcSEcCtD
Latanoprost—PTGFR—GPCRs, Class A Rhodopsin-like—SSTR1—pancreatic cancer	0.00139	0.0117	CbGpPWpGaD
Latanoprost—Angina pectoris—Fluorouracil—pancreatic cancer	0.00138	0.00453	CcSEcCtD
Latanoprost—Upper respiratory tract infection—Irinotecan—pancreatic cancer	0.00137	0.00451	CcSEcCtD
Latanoprost—Dermatitis atopic—Doxorubicin—pancreatic cancer	0.00137	0.00451	CcSEcCtD
Latanoprost—Stinging—Epirubicin—pancreatic cancer	0.00136	0.00445	CcSEcCtD
Latanoprost—PTGFR—GPCRs, Class A Rhodopsin-like—SSTR2—pancreatic cancer	0.00134	0.0112	CbGpPWpGaD
Latanoprost—SLCO2B1—Transmembrane transport of small molecules—FXYD3—pancreatic cancer	0.00132	0.0111	CbGpPWpGaD
Latanoprost—Upper respiratory tract infection—Fluorouracil—pancreatic cancer	0.00132	0.00432	CcSEcCtD
Latanoprost—PTGFR—G alpha (q) signalling events—CCK—pancreatic cancer	0.0013	0.0109	CbGpPWpGaD
Latanoprost—PTGFR—GPCRs, Class A Rhodopsin-like—CCKBR—pancreatic cancer	0.00129	0.0108	CbGpPWpGaD
Latanoprost—Mediastinal disorder—Sunitinib—pancreatic cancer	0.00129	0.00425	CcSEcCtD
Latanoprost—PTGFR—Gastrin-CREB signalling pathway via PKC and MAPK—GAST—pancreatic cancer	0.00129	0.0108	CbGpPWpGaD
Latanoprost—Stinging—Doxorubicin—pancreatic cancer	0.00125	0.00412	CcSEcCtD
Latanoprost—Erythema—Sunitinib—pancreatic cancer	0.00125	0.00411	CcSEcCtD
Latanoprost—PTGFR—G alpha (q) signalling events—CCKAR—pancreatic cancer	0.00125	0.0104	CbGpPWpGaD
Latanoprost—PTGFR—Class A/1 (Rhodopsin-like receptors)—SSTR3—pancreatic cancer	0.00124	0.0104	CbGpPWpGaD
Latanoprost—Arthralgia—Tamoxifen—pancreatic cancer	0.00124	0.00408	CcSEcCtD
Latanoprost—Chest pain—Tamoxifen—pancreatic cancer	0.00124	0.00408	CcSEcCtD
Latanoprost—Arthralgia—Erlotinib—pancreatic cancer	0.00123	0.00404	CcSEcCtD
Latanoprost—Chest pain—Erlotinib—pancreatic cancer	0.00123	0.00404	CcSEcCtD
Latanoprost—Discomfort—Tamoxifen—pancreatic cancer	0.00123	0.00403	CcSEcCtD
Latanoprost—Conjunctivitis—Fluorouracil—pancreatic cancer	0.00123	0.00403	CcSEcCtD
Latanoprost—Urinary tract infection—Fluorouracil—pancreatic cancer	0.00123	0.00403	CcSEcCtD
Latanoprost—Unspecified disorder of skin and subcutaneous tissue—Erlotinib—pancreatic cancer	0.00122	0.00401	CcSEcCtD
Latanoprost—Back pain—Sunitinib—pancreatic cancer	0.00121	0.00397	CcSEcCtD
Latanoprost—PTGFR—Class A/1 (Rhodopsin-like receptors)—SSTR1—pancreatic cancer	0.00119	0.00998	CbGpPWpGaD
Latanoprost—Lacrimation increased—Epirubicin—pancreatic cancer	0.00119	0.00392	CcSEcCtD
Latanoprost—Oedema—Tamoxifen—pancreatic cancer	0.00119	0.00391	CcSEcCtD
Latanoprost—Oedema—Erlotinib—pancreatic cancer	0.00118	0.00387	CcSEcCtD
Latanoprost—PTGFR—Class A/1 (Rhodopsin-like receptors)—PPY—pancreatic cancer	0.00117	0.00979	CbGpPWpGaD
Latanoprost—Tafluprost—PTGS2—pancreatic cancer	0.00117	1	CrCbGaD
Latanoprost—PTGFR—Gastrin-CREB signalling pathway via PKC and MAPK—CCK—pancreatic cancer	0.00116	0.00975	CbGpPWpGaD
Latanoprost—Connective tissue disorder—Irinotecan—pancreatic cancer	0.00116	0.00382	CcSEcCtD
Latanoprost—Nervous system disorder—Erlotinib—pancreatic cancer	0.00116	0.0038	CcSEcCtD
Latanoprost—PTGFR—Class A/1 (Rhodopsin-like receptors)—SSTR2—pancreatic cancer	0.00115	0.00961	CbGpPWpGaD
Latanoprost—Skin disorder—Erlotinib—pancreatic cancer	0.00114	0.00376	CcSEcCtD
Latanoprost—Connective tissue disorder—Gemcitabine—pancreatic cancer	0.00113	0.00372	CcSEcCtD
Latanoprost—Inflammation—Epirubicin—pancreatic cancer	0.00113	0.00372	CcSEcCtD
Latanoprost—PTGFR—Gastrin-CREB signalling pathway via PKC and MAPK—CCKAR—pancreatic cancer	0.00112	0.00935	CbGpPWpGaD
Latanoprost—PTGFR—GPCR ligand binding—PRLHR—pancreatic cancer	0.00111	0.00933	CbGpPWpGaD
Latanoprost—PTGFR—Class A/1 (Rhodopsin-like receptors)—CCKBR—pancreatic cancer	0.00111	0.00928	CbGpPWpGaD
Latanoprost—Lacrimation increased—Doxorubicin—pancreatic cancer	0.0011	0.00362	CcSEcCtD
Latanoprost—Musculoskeletal discomfort—Tamoxifen—pancreatic cancer	0.00109	0.00357	CcSEcCtD
Latanoprost—SLCO2B1—Transmembrane transport of small molecules—SLC29A1—pancreatic cancer	0.00108	0.00903	CbGpPWpGaD
Latanoprost—Musculoskeletal discomfort—Erlotinib—pancreatic cancer	0.00107	0.00353	CcSEcCtD
Latanoprost—Mediastinal disorder—Irinotecan—pancreatic cancer	0.00107	0.0035	CcSEcCtD
Latanoprost—Toxic epidermal necrolysis—Docetaxel—pancreatic cancer	0.00106	0.0035	CcSEcCtD
Latanoprost—Chest pain—Sunitinib—pancreatic cancer	0.00106	0.0035	CcSEcCtD
Latanoprost—Arthralgia—Sunitinib—pancreatic cancer	0.00106	0.0035	CcSEcCtD
Latanoprost—Dyspnoea—Tamoxifen—pancreatic cancer	0.00106	0.00349	CcSEcCtD
Latanoprost—Unspecified disorder of skin and subcutaneous tissue—Sunitinib—pancreatic cancer	0.00106	0.00347	CcSEcCtD
Latanoprost—Dyspnoea—Erlotinib—pancreatic cancer	0.00105	0.00345	CcSEcCtD
Latanoprost—Inflammation—Doxorubicin—pancreatic cancer	0.00105	0.00344	CcSEcCtD
Latanoprost—Mediastinal disorder—Gemcitabine—pancreatic cancer	0.00104	0.00341	CcSEcCtD
Latanoprost—Oedema—Sunitinib—pancreatic cancer	0.00102	0.00335	CcSEcCtD
Latanoprost—Pain—Tamoxifen—pancreatic cancer	0.00102	0.00335	CcSEcCtD
Latanoprost—Dry eye—Epirubicin—pancreatic cancer	0.00101	0.00333	CcSEcCtD
Latanoprost—Pain—Erlotinib—pancreatic cancer	0.00101	0.00331	CcSEcCtD
Latanoprost—Erythema—Gemcitabine—pancreatic cancer	0.001	0.0033	CcSEcCtD
Latanoprost—Nervous system disorder—Sunitinib—pancreatic cancer	0.001	0.00329	CcSEcCtD
Latanoprost—Back pain—Irinotecan—pancreatic cancer	0.000996	0.00327	CcSEcCtD
Latanoprost—Angina pectoris—Docetaxel—pancreatic cancer	0.000995	0.00327	CcSEcCtD
Latanoprost—Skin disorder—Sunitinib—pancreatic cancer	0.000991	0.00326	CcSEcCtD
Latanoprost—Erythema—Fluorouracil—pancreatic cancer	0.000986	0.00324	CcSEcCtD
Latanoprost—PTGFR—GPCRs, Class A Rhodopsin-like—CNR2—pancreatic cancer	0.000981	0.00821	CbGpPWpGaD
Latanoprost—Back pain—Gemcitabine—pancreatic cancer	0.00097	0.00319	CcSEcCtD
Latanoprost—PTGFR—GPCRs, Class A Rhodopsin-like—CCKAR—pancreatic cancer	0.000965	0.00808	CbGpPWpGaD
Latanoprost—SLC22A1—SLC-mediated transmembrane transport—SLC29A1—pancreatic cancer	0.000951	0.00796	CbGpPWpGaD
Latanoprost—PTGFR—GPCR ligand binding—SSTR3—pancreatic cancer	0.000948	0.00793	CbGpPWpGaD
Latanoprost—Dry eye—Doxorubicin—pancreatic cancer	0.000939	0.00308	CcSEcCtD
Latanoprost—Musculoskeletal discomfort—Sunitinib—pancreatic cancer	0.000929	0.00305	CcSEcCtD
Latanoprost—Vision blurred—Fluorouracil—pancreatic cancer	0.000929	0.00305	CcSEcCtD
Latanoprost—Hepatic function abnormal—Epirubicin—pancreatic cancer	0.000912	0.003	CcSEcCtD
Latanoprost—Dyspnoea—Sunitinib—pancreatic cancer	0.00091	0.00299	CcSEcCtD
Latanoprost—PTGFR—GPCR ligand binding—SSTR1—pancreatic cancer	0.000909	0.0076	CbGpPWpGaD
Latanoprost—PTGFR—GPCR ligand binding—PPY—pancreatic cancer	0.000891	0.00746	CbGpPWpGaD
Latanoprost—Eczema—Epirubicin—pancreatic cancer	0.000887	0.00291	CcSEcCtD
Latanoprost—Conjunctivitis—Docetaxel—pancreatic cancer	0.000885	0.00291	CcSEcCtD
Latanoprost—Eye pain—Epirubicin—pancreatic cancer	0.000883	0.0029	CcSEcCtD
Latanoprost—PTGFR—G alpha (q) signalling events—GCG—pancreatic cancer	0.00088	0.00736	CbGpPWpGaD
Latanoprost—PTGFR—GPCR ligand binding—SSTR2—pancreatic cancer	0.000875	0.00732	CbGpPWpGaD
Latanoprost—Pain—Sunitinib—pancreatic cancer	0.000872	0.00287	CcSEcCtD
Latanoprost—Discomfort—Irinotecan—pancreatic cancer	0.000866	0.00285	CcSEcCtD
Latanoprost—PTGFR—Class A/1 (Rhodopsin-like receptors)—CCK—pancreatic cancer	0.000863	0.00722	CbGpPWpGaD
Latanoprost—Chest pain—Gemcitabine—pancreatic cancer	0.000854	0.00281	CcSEcCtD
Latanoprost—Arthralgia—Gemcitabine—pancreatic cancer	0.000854	0.00281	CcSEcCtD
Latanoprost—Unspecified disorder of skin and subcutaneous tissue—Gemcitabine—pancreatic cancer	0.000848	0.00279	CcSEcCtD
Latanoprost—PTGFR—GPCR ligand binding—CCKBR—pancreatic cancer	0.000845	0.00707	CbGpPWpGaD
Latanoprost—Hepatic function abnormal—Doxorubicin—pancreatic cancer	0.000844	0.00277	CcSEcCtD
Latanoprost—Discomfort—Gemcitabine—pancreatic cancer	0.000844	0.00277	CcSEcCtD
Latanoprost—Pruritus—Tamoxifen—pancreatic cancer	0.000843	0.00277	CcSEcCtD
Latanoprost—PTGFR—Class A/1 (Rhodopsin-like receptors)—CNR2—pancreatic cancer	0.000841	0.00703	CbGpPWpGaD
Latanoprost—Oedema—Irinotecan—pancreatic cancer	0.00084	0.00276	CcSEcCtD
Latanoprost—Chest pain—Fluorouracil—pancreatic cancer	0.00084	0.00276	CcSEcCtD
Latanoprost—PTGFR—G alpha (q) signalling events—AGTR1—pancreatic cancer	0.000839	0.00702	CbGpPWpGaD
Latanoprost—Pruritus—Erlotinib—pancreatic cancer	0.000834	0.00274	CcSEcCtD
Latanoprost—Discomfort—Fluorouracil—pancreatic cancer	0.00083	0.00273	CcSEcCtD
Latanoprost—PTGFR—Class A/1 (Rhodopsin-like receptors)—CCKAR—pancreatic cancer	0.000827	0.00692	CbGpPWpGaD
Latanoprost—Nervous system disorder—Irinotecan—pancreatic cancer	0.000824	0.00271	CcSEcCtD
Latanoprost—Eczema—Doxorubicin—pancreatic cancer	0.000821	0.0027	CcSEcCtD
Latanoprost—Oedema—Gemcitabine—pancreatic cancer	0.000819	0.00269	CcSEcCtD
Latanoprost—Eye pain—Doxorubicin—pancreatic cancer	0.000817	0.00268	CcSEcCtD
Latanoprost—Oedema—Fluorouracil—pancreatic cancer	0.000805	0.00264	CcSEcCtD
Latanoprost—Connective tissue disorder—Docetaxel—pancreatic cancer	0.000804	0.00264	CcSEcCtD
Latanoprost—Nervous system disorder—Gemcitabine—pancreatic cancer	0.000803	0.00264	CcSEcCtD
Latanoprost—SLCO2B1—SLC-mediated transmembrane transport—SLC2A2—pancreatic cancer	0.000802	0.00671	CbGpPWpGaD
Latanoprost—Diplopia—Epirubicin—pancreatic cancer	0.000797	0.00262	CcSEcCtD
Latanoprost—Skin disorder—Gemcitabine—pancreatic cancer	0.000795	0.00261	CcSEcCtD
Latanoprost—SLC22A1—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC2A2—pancreatic cancer	0.000791	0.00662	CbGpPWpGaD
Latanoprost—Nervous system disorder—Fluorouracil—pancreatic cancer	0.000789	0.00259	CcSEcCtD
Latanoprost—Dizziness—Tamoxifen—pancreatic cancer	0.000788	0.00259	CcSEcCtD
Latanoprost—PTGFR—Gastrin-CREB signalling pathway via PKC and MAPK—GCG—pancreatic cancer	0.000787	0.00658	CbGpPWpGaD
Latanoprost—Dizziness—Erlotinib—pancreatic cancer	0.000779	0.00256	CcSEcCtD
Latanoprost—Rash—Tamoxifen—pancreatic cancer	0.000751	0.00247	CcSEcCtD
Latanoprost—PTGFR—Gastrin-CREB signalling pathway via PKC and MAPK—AGTR1—pancreatic cancer	0.000751	0.00628	CbGpPWpGaD
Latanoprost—Dermatitis—Tamoxifen—pancreatic cancer	0.00075	0.00247	CcSEcCtD
Latanoprost—Dyspnoea—Irinotecan—pancreatic cancer	0.000749	0.00246	CcSEcCtD
Latanoprost—Headache—Tamoxifen—pancreatic cancer	0.000746	0.00245	CcSEcCtD
Latanoprost—Musculoskeletal discomfort—Gemcitabine—pancreatic cancer	0.000746	0.00245	CcSEcCtD
Latanoprost—Rash—Erlotinib—pancreatic cancer	0.000743	0.00244	CcSEcCtD
Latanoprost—Dermatitis—Erlotinib—pancreatic cancer	0.000742	0.00244	CcSEcCtD
Latanoprost—Headache—Erlotinib—pancreatic cancer	0.000738	0.00243	CcSEcCtD
Latanoprost—Diplopia—Doxorubicin—pancreatic cancer	0.000738	0.00242	CcSEcCtD
Latanoprost—Mediastinal disorder—Docetaxel—pancreatic cancer	0.000737	0.00242	CcSEcCtD
Latanoprost—Musculoskeletal discomfort—Fluorouracil—pancreatic cancer	0.000733	0.00241	CcSEcCtD
Latanoprost—Dyspnoea—Gemcitabine—pancreatic cancer	0.00073	0.0024	CcSEcCtD
Latanoprost—Pruritus—Sunitinib—pancreatic cancer	0.000722	0.00237	CcSEcCtD
Latanoprost—Pain—Irinotecan—pancreatic cancer	0.000719	0.00236	CcSEcCtD
Latanoprost—Toxic epidermal necrolysis—Epirubicin—pancreatic cancer	0.000718	0.00236	CcSEcCtD
Latanoprost—Dyspnoea—Fluorouracil—pancreatic cancer	0.000718	0.00236	CcSEcCtD
Latanoprost—Erythema—Docetaxel—pancreatic cancer	0.000712	0.00234	CcSEcCtD
Latanoprost—PTGFR—GPCRs, Class A Rhodopsin-like—CNR1—pancreatic cancer	0.000704	0.00589	CbGpPWpGaD
Latanoprost—Pain—Gemcitabine—pancreatic cancer	0.0007	0.0023	CcSEcCtD
Latanoprost—Asthma—Epirubicin—pancreatic cancer	0.000689	0.00226	CcSEcCtD
Latanoprost—PTGFR—GPCR ligand binding—SCT—pancreatic cancer	0.000689	0.00576	CbGpPWpGaD
Latanoprost—Back pain—Docetaxel—pancreatic cancer	0.000689	0.00226	CcSEcCtD
Latanoprost—Pain—Fluorouracil—pancreatic cancer	0.000688	0.00226	CcSEcCtD
Latanoprost—Dizziness—Sunitinib—pancreatic cancer	0.000675	0.00222	CcSEcCtD
Latanoprost—Angina pectoris—Epirubicin—pancreatic cancer	0.000671	0.00221	CcSEcCtD
Latanoprost—Toxic epidermal necrolysis—Doxorubicin—pancreatic cancer	0.000664	0.00218	CcSEcCtD
Latanoprost—Bronchitis—Epirubicin—pancreatic cancer	0.000663	0.00218	CcSEcCtD
Latanoprost—PTGFR—GPCR ligand binding—CCK—pancreatic cancer	0.000657	0.0055	CbGpPWpGaD
Latanoprost—PTGFR—Class A/1 (Rhodopsin-like receptors)—SST—pancreatic cancer	0.000654	0.00547	CbGpPWpGaD
Latanoprost—PTGFR—GPCRs, Class A Rhodopsin-like—AGTR1—pancreatic cancer	0.000649	0.00543	CbGpPWpGaD
Latanoprost—Rash—Sunitinib—pancreatic cancer	0.000643	0.00211	CcSEcCtD
Latanoprost—Dermatitis—Sunitinib—pancreatic cancer	0.000643	0.00211	CcSEcCtD
Latanoprost—Upper respiratory tract infection—Epirubicin—pancreatic cancer	0.00064	0.0021	CcSEcCtD
Latanoprost—PTGFR—GPCR ligand binding—GLP1R—pancreatic cancer	0.00064	0.00536	CbGpPWpGaD
Latanoprost—PTGFR—GPCR ligand binding—CNR2—pancreatic cancer	0.00064	0.00536	CbGpPWpGaD
Latanoprost—Headache—Sunitinib—pancreatic cancer	0.000639	0.0021	CcSEcCtD
Latanoprost—Asthma—Doxorubicin—pancreatic cancer	0.000638	0.00209	CcSEcCtD
Latanoprost—PTGFR—GPCR ligand binding—CCKAR—pancreatic cancer	0.00063	0.00527	CbGpPWpGaD
Latanoprost—Angina pectoris—Doxorubicin—pancreatic cancer	0.000621	0.00204	CcSEcCtD
Latanoprost—Bronchitis—Doxorubicin—pancreatic cancer	0.000613	0.00201	CcSEcCtD
Latanoprost—Chest pain—Docetaxel—pancreatic cancer	0.000606	0.00199	CcSEcCtD
Latanoprost—Arthralgia—Docetaxel—pancreatic cancer	0.000606	0.00199	CcSEcCtD
Latanoprost—PTGFR—Class A/1 (Rhodopsin-like receptors)—CNR1—pancreatic cancer	0.000603	0.00505	CbGpPWpGaD
Latanoprost—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—pancreatic cancer	0.000602	0.00198	CcSEcCtD
Latanoprost—Conjunctivitis—Epirubicin—pancreatic cancer	0.000597	0.00196	CcSEcCtD
Latanoprost—Urinary tract infection—Epirubicin—pancreatic cancer	0.000597	0.00196	CcSEcCtD
Latanoprost—SLC22A1—Transmembrane transport of small molecules—FXYD3—pancreatic cancer	0.000593	0.00496	CbGpPWpGaD
Latanoprost—Upper respiratory tract infection—Doxorubicin—pancreatic cancer	0.000593	0.00195	CcSEcCtD
Latanoprost—Oedema—Docetaxel—pancreatic cancer	0.000581	0.00191	CcSEcCtD
Latanoprost—Pruritus—Gemcitabine—pancreatic cancer	0.000579	0.0019	CcSEcCtD
Latanoprost—PTGFR—GPCR ligand binding—SHH—pancreatic cancer	0.000574	0.0048	CbGpPWpGaD
Latanoprost—PTGFR—Signaling by GPCR—PRLHR—pancreatic cancer	0.000572	0.00479	CbGpPWpGaD
Latanoprost—Nervous system disorder—Docetaxel—pancreatic cancer	0.00057	0.00187	CcSEcCtD
Latanoprost—Pruritus—Fluorouracil—pancreatic cancer	0.000569	0.00187	CcSEcCtD
Latanoprost—PTGFR—GPCR ligand binding—IAPP—pancreatic cancer	0.000567	0.00474	CbGpPWpGaD
Latanoprost—Skin disorder—Docetaxel—pancreatic cancer	0.000564	0.00185	CcSEcCtD
Latanoprost—PTGFR—Class A/1 (Rhodopsin-like receptors)—AGTR1—pancreatic cancer	0.000556	0.00465	CbGpPWpGaD
Latanoprost—Dizziness—Irinotecan—pancreatic cancer	0.000556	0.00183	CcSEcCtD
Latanoprost—Urinary tract infection—Doxorubicin—pancreatic cancer	0.000553	0.00182	CcSEcCtD
Latanoprost—Conjunctivitis—Doxorubicin—pancreatic cancer	0.000553	0.00182	CcSEcCtD
Latanoprost—PTGFR—GPCR ligand binding—PTHLH—pancreatic cancer	0.000544	0.00455	CbGpPWpGaD
Latanoprost—PTGFR—GPCR ligand binding—PTCH1—pancreatic cancer	0.000544	0.00455	CbGpPWpGaD
Latanoprost—Connective tissue disorder—Epirubicin—pancreatic cancer	0.000542	0.00178	CcSEcCtD
Latanoprost—PTGFR—GPCR downstream signaling—SSTR3—pancreatic cancer	0.000536	0.00448	CbGpPWpGaD
Latanoprost—Dizziness—Fluorouracil—pancreatic cancer	0.000532	0.00175	CcSEcCtD
Latanoprost—Rash—Irinotecan—pancreatic cancer	0.00053	0.00174	CcSEcCtD
Latanoprost—Dermatitis—Irinotecan—pancreatic cancer	0.000529	0.00174	CcSEcCtD
Latanoprost—Musculoskeletal discomfort—Docetaxel—pancreatic cancer	0.000529	0.00174	CcSEcCtD
Latanoprost—Headache—Irinotecan—pancreatic cancer	0.000526	0.00173	CcSEcCtD
Latanoprost—PTGFR—Signaling Pathways—GDI1—pancreatic cancer	0.000524	0.00439	CbGpPWpGaD
Latanoprost—PTGFR—Signaling Pathways—GDI2—pancreatic cancer	0.000524	0.00439	CbGpPWpGaD
Latanoprost—Dyspnoea—Docetaxel—pancreatic cancer	0.000518	0.0017	CcSEcCtD
Latanoprost—Rash—Gemcitabine—pancreatic cancer	0.000516	0.0017	CcSEcCtD
Latanoprost—Dermatitis—Gemcitabine—pancreatic cancer	0.000516	0.00169	CcSEcCtD
Latanoprost—PTGFR—GPCR downstream signaling—SSTR1—pancreatic cancer	0.000513	0.0043	CbGpPWpGaD
Latanoprost—Headache—Gemcitabine—pancreatic cancer	0.000513	0.00169	CcSEcCtD
Latanoprost—Rash—Fluorouracil—pancreatic cancer	0.000507	0.00167	CcSEcCtD
Latanoprost—Dermatitis—Fluorouracil—pancreatic cancer	0.000507	0.00167	CcSEcCtD
Latanoprost—Headache—Fluorouracil—pancreatic cancer	0.000504	0.00166	CcSEcCtD
Latanoprost—PTGFR—GPCR downstream signaling—PPY—pancreatic cancer	0.000504	0.00421	CbGpPWpGaD
Latanoprost—Connective tissue disorder—Doxorubicin—pancreatic cancer	0.000501	0.00165	CcSEcCtD
Latanoprost—PTGFR—GPCR ligand binding—SST—pancreatic cancer	0.000498	0.00417	CbGpPWpGaD
Latanoprost—Mediastinal disorder—Epirubicin—pancreatic cancer	0.000497	0.00163	CcSEcCtD
Latanoprost—Pain—Docetaxel—pancreatic cancer	0.000497	0.00163	CcSEcCtD
Latanoprost—PTGFR—GPCR downstream signaling—SSTR2—pancreatic cancer	0.000494	0.00414	CbGpPWpGaD
Latanoprost—PTGFR—Signaling by GPCR—SSTR3—pancreatic cancer	0.000486	0.00407	CbGpPWpGaD
Latanoprost—SLC22A1—Transmembrane transport of small molecules—SLC29A1—pancreatic cancer	0.000483	0.00404	CbGpPWpGaD
Latanoprost—Erythema—Epirubicin—pancreatic cancer	0.00048	0.00158	CcSEcCtD
Latanoprost—PTGFR—GPCR downstream signaling—CCKBR—pancreatic cancer	0.000477	0.00399	CbGpPWpGaD
Latanoprost—PTGFR—Signaling by GPCR—SSTR1—pancreatic cancer	0.000466	0.0039	CbGpPWpGaD
Latanoprost—Back pain—Epirubicin—pancreatic cancer	0.000464	0.00153	CcSEcCtD
Latanoprost—Mediastinal disorder—Doxorubicin—pancreatic cancer	0.00046	0.00151	CcSEcCtD
Latanoprost—PTGFR—GPCR ligand binding—CNR1—pancreatic cancer	0.000459	0.00384	CbGpPWpGaD
Latanoprost—PTGFR—Signaling by GPCR—PPY—pancreatic cancer	0.000457	0.00383	CbGpPWpGaD
Latanoprost—Vision blurred—Epirubicin—pancreatic cancer	0.000452	0.00149	CcSEcCtD
Latanoprost—PTGFR—Signaling by GPCR—SSTR2—pancreatic cancer	0.000449	0.00376	CbGpPWpGaD
Latanoprost—Erythema—Doxorubicin—pancreatic cancer	0.000444	0.00146	CcSEcCtD
Latanoprost—PTGFR—GPCR ligand binding—GCG—pancreatic cancer	0.000444	0.00371	CbGpPWpGaD
Latanoprost—PTGFR—Signaling by GPCR—CCKBR—pancreatic cancer	0.000434	0.00363	CbGpPWpGaD
Latanoprost—Back pain—Doxorubicin—pancreatic cancer	0.00043	0.00141	CcSEcCtD
Latanoprost—PTGFR—GPCR ligand binding—AGTR1—pancreatic cancer	0.000423	0.00354	CbGpPWpGaD
Latanoprost—Vision blurred—Doxorubicin—pancreatic cancer	0.000419	0.00138	CcSEcCtD
Latanoprost—Pruritus—Docetaxel—pancreatic cancer	0.000411	0.00135	CcSEcCtD
Latanoprost—PTGFR—GPCR downstream signaling—GAST—pancreatic cancer	0.000411	0.00343	CbGpPWpGaD
Latanoprost—Arthralgia—Epirubicin—pancreatic cancer	0.000409	0.00134	CcSEcCtD
Latanoprost—Chest pain—Epirubicin—pancreatic cancer	0.000409	0.00134	CcSEcCtD
Latanoprost—SLCO2B1—Transmembrane transport of small molecules—SLC2A2—pancreatic cancer	0.000407	0.00341	CbGpPWpGaD
Latanoprost—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—pancreatic cancer	0.000406	0.00133	CcSEcCtD
Latanoprost—Discomfort—Epirubicin—pancreatic cancer	0.000404	0.00133	CcSEcCtD
Latanoprost—Oedema—Epirubicin—pancreatic cancer	0.000392	0.00129	CcSEcCtD
Latanoprost—PTGFR—GPCR downstream signaling—SCT—pancreatic cancer	0.000389	0.00326	CbGpPWpGaD
Latanoprost—Nervous system disorder—Epirubicin—pancreatic cancer	0.000384	0.00126	CcSEcCtD
Latanoprost—Dizziness—Docetaxel—pancreatic cancer	0.000384	0.00126	CcSEcCtD
Latanoprost—Skin disorder—Epirubicin—pancreatic cancer	0.000381	0.00125	CcSEcCtD
Latanoprost—Arthralgia—Doxorubicin—pancreatic cancer	0.000378	0.00124	CcSEcCtD
Latanoprost—Chest pain—Doxorubicin—pancreatic cancer	0.000378	0.00124	CcSEcCtD
Latanoprost—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—pancreatic cancer	0.000376	0.00123	CcSEcCtD
Latanoprost—Discomfort—Doxorubicin—pancreatic cancer	0.000374	0.00123	CcSEcCtD
Latanoprost—PTGFR—Signaling by GPCR—GAST—pancreatic cancer	0.000373	0.00312	CbGpPWpGaD
Latanoprost—PTGFR—GPCR downstream signaling—CCK—pancreatic cancer	0.000371	0.00311	CbGpPWpGaD
Latanoprost—Rash—Docetaxel—pancreatic cancer	0.000366	0.0012	CcSEcCtD
Latanoprost—Dermatitis—Docetaxel—pancreatic cancer	0.000366	0.0012	CcSEcCtD
Latanoprost—Headache—Docetaxel—pancreatic cancer	0.000364	0.0012	CcSEcCtD
Latanoprost—Oedema—Doxorubicin—pancreatic cancer	0.000363	0.00119	CcSEcCtD
Latanoprost—PTGFR—GPCR downstream signaling—CNR2—pancreatic cancer	0.000362	0.00303	CbGpPWpGaD
Latanoprost—PTGFR—GPCR downstream signaling—GLP1R—pancreatic cancer	0.000362	0.00303	CbGpPWpGaD
Latanoprost—SLC22A1—SLC-mediated transmembrane transport—SLC2A2—pancreatic cancer	0.000359	0.00301	CbGpPWpGaD
Latanoprost—Musculoskeletal discomfort—Epirubicin—pancreatic cancer	0.000357	0.00117	CcSEcCtD
Latanoprost—PTGFR—GPCR downstream signaling—CCKAR—pancreatic cancer	0.000356	0.00298	CbGpPWpGaD
Latanoprost—Nervous system disorder—Doxorubicin—pancreatic cancer	0.000356	0.00117	CcSEcCtD
Latanoprost—PTGFR—Signaling by GPCR—SCT—pancreatic cancer	0.000353	0.00296	CbGpPWpGaD
Latanoprost—Skin disorder—Doxorubicin—pancreatic cancer	0.000352	0.00116	CcSEcCtD
Latanoprost—Dyspnoea—Epirubicin—pancreatic cancer	0.000349	0.00115	CcSEcCtD
Latanoprost—PTGFR—Signaling Pathways—PRLHR—pancreatic cancer	0.000338	0.00283	CbGpPWpGaD
Latanoprost—PTGFR—Signaling by GPCR—CCK—pancreatic cancer	0.000337	0.00282	CbGpPWpGaD
Latanoprost—Pain—Epirubicin—pancreatic cancer	0.000335	0.0011	CcSEcCtD
Latanoprost—Musculoskeletal discomfort—Doxorubicin—pancreatic cancer	0.00033	0.00109	CcSEcCtD
Latanoprost—PTGFR—Signaling by GPCR—GLP1R—pancreatic cancer	0.000329	0.00275	CbGpPWpGaD
Latanoprost—PTGFR—Signaling by GPCR—CNR2—pancreatic cancer	0.000329	0.00275	CbGpPWpGaD
Latanoprost—Dyspnoea—Doxorubicin—pancreatic cancer	0.000323	0.00106	CcSEcCtD
Latanoprost—PTGFR—Signaling by GPCR—CCKAR—pancreatic cancer	0.000323	0.0027	CbGpPWpGaD
Latanoprost—PTGFR—GPCR downstream signaling—IAPP—pancreatic cancer	0.00032	0.00268	CbGpPWpGaD
Latanoprost—PTGFR—Signaling Pathways—ACVR1B—pancreatic cancer	0.000318	0.00266	CbGpPWpGaD
Latanoprost—PTGFR—Signaling Pathways—ZNRF3—pancreatic cancer	0.000318	0.00266	CbGpPWpGaD
Latanoprost—Pain—Doxorubicin—pancreatic cancer	0.00031	0.00102	CcSEcCtD
Latanoprost—PTGFR—GPCR downstream signaling—PTHLH—pancreatic cancer	0.000308	0.00257	CbGpPWpGaD
Latanoprost—PTGFR—Signaling by GPCR—SHH—pancreatic cancer	0.000295	0.00247	CbGpPWpGaD
Latanoprost—PTGFR—Signaling by GPCR—IAPP—pancreatic cancer	0.000291	0.00244	CbGpPWpGaD
Latanoprost—PTGFR—Signaling Pathways—DTX1—pancreatic cancer	0.000287	0.0024	CbGpPWpGaD
Latanoprost—PTGFR—Signaling Pathways—SSTR3—pancreatic cancer	0.000287	0.0024	CbGpPWpGaD
Latanoprost—PTGFR—GPCR downstream signaling—SST—pancreatic cancer	0.000281	0.00235	CbGpPWpGaD
Latanoprost—PTGFR—Signaling by GPCR—PTCH1—pancreatic cancer	0.000279	0.00234	CbGpPWpGaD
Latanoprost—PTGFR—Signaling by GPCR—PTHLH—pancreatic cancer	0.000279	0.00234	CbGpPWpGaD
Latanoprost—Pruritus—Epirubicin—pancreatic cancer	0.000277	0.000911	CcSEcCtD
Latanoprost—PTGFR—Gastrin-CREB signalling pathway via PKC and MAPK—NRAS—pancreatic cancer	0.000276	0.00231	CbGpPWpGaD
Latanoprost—PTGFR—Signaling Pathways—SSTR1—pancreatic cancer	0.000275	0.0023	CbGpPWpGaD
Latanoprost—PTGFR—Signaling Pathways—PPY—pancreatic cancer	0.00027	0.00226	CbGpPWpGaD
Latanoprost—PTGFR—Signaling Pathways—SSTR2—pancreatic cancer	0.000265	0.00222	CbGpPWpGaD
Latanoprost—PTGFR—GPCR downstream signaling—CNR1—pancreatic cancer	0.00026	0.00217	CbGpPWpGaD
Latanoprost—Dizziness—Epirubicin—pancreatic cancer	0.000259	0.000851	CcSEcCtD
Latanoprost—Pruritus—Doxorubicin—pancreatic cancer	0.000257	0.000843	CcSEcCtD
Latanoprost—PTGFR—Signaling Pathways—CCKBR—pancreatic cancer	0.000256	0.00214	CbGpPWpGaD
Latanoprost—PTGFR—Signaling by GPCR—SST—pancreatic cancer	0.000255	0.00214	CbGpPWpGaD
Latanoprost—PTGFR—Class A/1 (Rhodopsin-like receptors)—CXCL8—pancreatic cancer	0.000255	0.00213	CbGpPWpGaD
Latanoprost—PTGFR—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—pancreatic cancer	0.000251	0.0021	CbGpPWpGaD
Latanoprost—PTGFR—GPCR downstream signaling—GCG—pancreatic cancer	0.000251	0.0021	CbGpPWpGaD
Latanoprost—Rash—Epirubicin—pancreatic cancer	0.000247	0.000812	CcSEcCtD
Latanoprost—Dermatitis—Epirubicin—pancreatic cancer	0.000247	0.000811	CcSEcCtD
Latanoprost—Headache—Epirubicin—pancreatic cancer	0.000245	0.000807	CcSEcCtD
Latanoprost—PTGFR—G alpha (q) signalling events—PIK3CA—pancreatic cancer	0.000244	0.00204	CbGpPWpGaD
Latanoprost—PTGFR—Signaling Pathways—DTX4—pancreatic cancer	0.000241	0.00201	CbGpPWpGaD
Latanoprost—PTGFR—Signaling Pathways—GLI1—pancreatic cancer	0.000241	0.00201	CbGpPWpGaD
Latanoprost—Dizziness—Doxorubicin—pancreatic cancer	0.00024	0.000788	CcSEcCtD
Latanoprost—PTGFR—GPCR downstream signaling—AGTR1—pancreatic cancer	0.000239	0.002	CbGpPWpGaD
Latanoprost—PTGFR—Gastrin-CREB signalling pathway via PKC and MAPK—KRAS—pancreatic cancer	0.000238	0.00199	CbGpPWpGaD
Latanoprost—PTGFR—Signaling by GPCR—CNR1—pancreatic cancer	0.000236	0.00197	CbGpPWpGaD
Latanoprost—PTGFR—Signaling Pathways—NRP1—pancreatic cancer	0.000234	0.00196	CbGpPWpGaD
Latanoprost—PTGFR—Signaling Pathways—PPP2R5B—pancreatic cancer	0.000234	0.00196	CbGpPWpGaD
Latanoprost—Rash—Doxorubicin—pancreatic cancer	0.000229	0.000751	CcSEcCtD
Latanoprost—Dermatitis—Doxorubicin—pancreatic cancer	0.000228	0.00075	CcSEcCtD
Latanoprost—PTGFR—Signaling by GPCR—GCG—pancreatic cancer	0.000228	0.00191	CbGpPWpGaD
Latanoprost—Headache—Doxorubicin—pancreatic cancer	0.000227	0.000746	CcSEcCtD
Latanoprost—PTGFR—Signaling Pathways—HEY2—pancreatic cancer	0.000225	0.00189	CbGpPWpGaD
Latanoprost—PTGFR—Signaling Pathways—GAST—pancreatic cancer	0.00022	0.00184	CbGpPWpGaD
Latanoprost—PTGFR—Gastrin-CREB signalling pathway via PKC and MAPK—PIK3CA—pancreatic cancer	0.000218	0.00183	CbGpPWpGaD
Latanoprost—PTGFR—Signaling by GPCR—AGTR1—pancreatic cancer	0.000217	0.00182	CbGpPWpGaD
Latanoprost—PTGFR—Signaling Pathways—SCT—pancreatic cancer	0.000209	0.00175	CbGpPWpGaD
Latanoprost—PTGFR—Signaling Pathways—HEY1—pancreatic cancer	0.000209	0.00175	CbGpPWpGaD
Latanoprost—PTGFR—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—pancreatic cancer	0.000202	0.00169	CbGpPWpGaD
Latanoprost—PTGFR—Signaling Pathways—CCK—pancreatic cancer	0.000199	0.00167	CbGpPWpGaD
Latanoprost—PTGFR—Signaling Pathways—CNR2—pancreatic cancer	0.000194	0.00162	CbGpPWpGaD
Latanoprost—PTGFR—Signaling Pathways—GLP1R—pancreatic cancer	0.000194	0.00162	CbGpPWpGaD
Latanoprost—PTGFR—GPCR ligand binding—CXCL8—pancreatic cancer	0.000194	0.00162	CbGpPWpGaD
Latanoprost—PTGFR—Signaling Pathways—CCKAR—pancreatic cancer	0.000191	0.0016	CbGpPWpGaD
Latanoprost—PTGFR—Signaling Pathways—JAG2—pancreatic cancer	0.000185	0.00155	CbGpPWpGaD
Latanoprost—SLC22A1—Transmembrane transport of small molecules—SLC2A2—pancreatic cancer	0.000183	0.00153	CbGpPWpGaD
Latanoprost—PTGFR—Signaling Pathways—MEN1—pancreatic cancer	0.000182	0.00153	CbGpPWpGaD
Latanoprost—PTGFR—Signaling Pathways—SHH—pancreatic cancer	0.000174	0.00146	CbGpPWpGaD
Latanoprost—PTGFR—Signaling Pathways—NOTCH4—pancreatic cancer	0.000173	0.00145	CbGpPWpGaD
Latanoprost—PTGFR—Signaling Pathways—IAPP—pancreatic cancer	0.000172	0.00144	CbGpPWpGaD
Latanoprost—PTGFR—Signaling Pathways—PTCH1—pancreatic cancer	0.000165	0.00138	CbGpPWpGaD
Latanoprost—PTGFR—Signaling Pathways—PTHLH—pancreatic cancer	0.000165	0.00138	CbGpPWpGaD
Latanoprost—PTGFR—Signaling Pathways—SST—pancreatic cancer	0.000151	0.00126	CbGpPWpGaD
Latanoprost—SLC22A1—Metabolism—PRSS1—pancreatic cancer	0.00015	0.00125	CbGpPWpGaD
Latanoprost—PTGFR—GPCR downstream signaling—PIK3CG—pancreatic cancer	0.000149	0.00125	CbGpPWpGaD
Latanoprost—PTGFR—Signaling Pathways—JAG1—pancreatic cancer	0.000148	0.00124	CbGpPWpGaD
Latanoprost—PTGFR—Signaling Pathways—NOTCH3—pancreatic cancer	0.000147	0.00123	CbGpPWpGaD
Latanoprost—PTGFR—Signaling Pathways—CNR1—pancreatic cancer	0.000139	0.00117	CbGpPWpGaD
Latanoprost—PTGFR—Signaling by GPCR—PIK3CG—pancreatic cancer	0.000135	0.00113	CbGpPWpGaD
Latanoprost—PTGFR—Signaling Pathways—GCG—pancreatic cancer	0.000135	0.00113	CbGpPWpGaD
Latanoprost—PTGFR—GPCR downstream signaling—PIK3CD—pancreatic cancer	0.000131	0.00109	CbGpPWpGaD
Latanoprost—SLC22A1—Metabolism—ARG2—pancreatic cancer	0.00013	0.00109	CbGpPWpGaD
Latanoprost—PTGFR—Signaling Pathways—AGTR1—pancreatic cancer	0.000128	0.00107	CbGpPWpGaD
Latanoprost—PTGFR—Signaling Pathways—STK11—pancreatic cancer	0.000126	0.00106	CbGpPWpGaD
Latanoprost—PTGFR—Signaling by GPCR—PIK3CD—pancreatic cancer	0.000119	0.000994	CbGpPWpGaD
Latanoprost—PTGFR—GPCR downstream signaling—PIK3CB—pancreatic cancer	0.000114	0.000954	CbGpPWpGaD
Latanoprost—SLC22A1—Metabolism—TYMP—pancreatic cancer	0.000114	0.000951	CbGpPWpGaD
Latanoprost—PTGFR—Signaling Pathways—SMAD4—pancreatic cancer	0.000111	0.000927	CbGpPWpGaD
Latanoprost—PTGFR—GPCR downstream signaling—CXCL8—pancreatic cancer	0.00011	0.000917	CbGpPWpGaD
Latanoprost—PTGFR—Signaling Pathways—HES1—pancreatic cancer	0.000108	0.000905	CbGpPWpGaD
Latanoprost—PTGFR—Signaling by GPCR—PIK3CB—pancreatic cancer	0.000104	0.000867	CbGpPWpGaD
Latanoprost—PTGFR—Signaling by GPCR—CXCL8—pancreatic cancer	9.95e-05	0.000833	CbGpPWpGaD
Latanoprost—PTGFR—Signaling Pathways—TERT—pancreatic cancer	9.48e-05	0.000793	CbGpPWpGaD
Latanoprost—SLC22A1—Metabolism—GLP1R—pancreatic cancer	9.16e-05	0.000766	CbGpPWpGaD
Latanoprost—PTGFR—Signaling Pathways—HIF1A—pancreatic cancer	9.06e-05	0.000758	CbGpPWpGaD
Latanoprost—PTGFR—Signaling Pathways—TSC2—pancreatic cancer	9.04e-05	0.000757	CbGpPWpGaD
Latanoprost—SLC22A1—Metabolism—DPYD—pancreatic cancer	9.01e-05	0.000754	CbGpPWpGaD
Latanoprost—PTGFR—Signaling Pathways—APOE—pancreatic cancer	8.85e-05	0.00074	CbGpPWpGaD
Latanoprost—PTGFR—Signaling Pathways—KDR—pancreatic cancer	8.67e-05	0.000725	CbGpPWpGaD
Latanoprost—SLC22A1—Metabolism—SLC2A2—pancreatic cancer	8.55e-05	0.000716	CbGpPWpGaD
Latanoprost—SLC22A1—Transmission across Chemical Synapses—HRAS—pancreatic cancer	8.44e-05	0.000706	CbGpPWpGaD
Latanoprost—PTGFR—Signaling Pathways—NFKBIA—pancreatic cancer	8.25e-05	0.00069	CbGpPWpGaD
Latanoprost—PTGFR—Signaling Pathways—NOTCH1—pancreatic cancer	8.17e-05	0.000683	CbGpPWpGaD
Latanoprost—PTGFR—Signaling Pathways—PIK3CG—pancreatic cancer	7.99e-05	0.000668	CbGpPWpGaD
Latanoprost—PTGFR—Signaling by GPCR—NRAS—pancreatic cancer	7.99e-05	0.000668	CbGpPWpGaD
Latanoprost—PTGFR—Signaling Pathways—EGF—pancreatic cancer	7.89e-05	0.00066	CbGpPWpGaD
Latanoprost—PTGFR—Signaling by GPCR—EGFR—pancreatic cancer	7.28e-05	0.000609	CbGpPWpGaD
Latanoprost—PTGFR—Signaling Pathways—PIK3CD—pancreatic cancer	7.02e-05	0.000587	CbGpPWpGaD
Latanoprost—PTGFR—GPCR downstream signaling—PIK3CA—pancreatic cancer	6.95e-05	0.000582	CbGpPWpGaD
Latanoprost—PTGFR—Signaling by GPCR—KRAS—pancreatic cancer	6.87e-05	0.000575	CbGpPWpGaD
Latanoprost—SLC22A1—Metabolism—CD44—pancreatic cancer	6.62e-05	0.000554	CbGpPWpGaD
Latanoprost—SLC22A1—Neuronal System—HRAS—pancreatic cancer	6.47e-05	0.000541	CbGpPWpGaD
Latanoprost—SLC22A1—Metabolism—GCG—pancreatic cancer	6.35e-05	0.000531	CbGpPWpGaD
Latanoprost—PTGFR—Signaling by GPCR—PIK3CA—pancreatic cancer	6.31e-05	0.000528	CbGpPWpGaD
Latanoprost—PTGFR—Signaling Pathways—PIK3CB—pancreatic cancer	6.12e-05	0.000512	CbGpPWpGaD
Latanoprost—SLC22A1—Metabolism—STK11—pancreatic cancer	5.97e-05	0.0005	CbGpPWpGaD
Latanoprost—PTGFR—Signaling Pathways—CXCL8—pancreatic cancer	5.88e-05	0.000492	CbGpPWpGaD
Latanoprost—PTGFR—Signaling by GPCR—HRAS—pancreatic cancer	5.84e-05	0.000489	CbGpPWpGaD
Latanoprost—PTGFR—GPCR downstream signaling—AKT1—pancreatic cancer	5.68e-05	0.000475	CbGpPWpGaD
Latanoprost—PTGFR—Signaling Pathways—CASP3—pancreatic cancer	5.63e-05	0.000471	CbGpPWpGaD
Latanoprost—PTGFR—Signaling Pathways—CCND1—pancreatic cancer	5.48e-05	0.000458	CbGpPWpGaD
Latanoprost—PTGFR—Signaling Pathways—CTNNB1—pancreatic cancer	5.42e-05	0.000454	CbGpPWpGaD
Latanoprost—PTGFR—Signaling Pathways—MMP9—pancreatic cancer	5.32e-05	0.000445	CbGpPWpGaD
Latanoprost—PTGFR—Signaling Pathways—PTEN—pancreatic cancer	5.29e-05	0.000442	CbGpPWpGaD
Latanoprost—PTGFR—Signaling by GPCR—AKT1—pancreatic cancer	5.16e-05	0.000432	CbGpPWpGaD
Latanoprost—SLC22A1—Metabolism—TYMS—pancreatic cancer	5.14e-05	0.00043	CbGpPWpGaD
Latanoprost—PTGFR—Signaling Pathways—SRC—pancreatic cancer	4.9e-05	0.00041	CbGpPWpGaD
Latanoprost—PTGFR—Signaling Pathways—VEGFA—pancreatic cancer	4.78e-05	0.0004	CbGpPWpGaD
Latanoprost—PTGFR—Signaling Pathways—STAT3—pancreatic cancer	4.73e-05	0.000396	CbGpPWpGaD
Latanoprost—PTGFR—Signaling Pathways—NRAS—pancreatic cancer	4.72e-05	0.000395	CbGpPWpGaD
Latanoprost—PTGFR—Signaling Pathways—MYC—pancreatic cancer	4.39e-05	0.000368	CbGpPWpGaD
Latanoprost—PTGFR—Signaling Pathways—TGFB1—pancreatic cancer	4.38e-05	0.000367	CbGpPWpGaD
Latanoprost—PTGFR—Signaling Pathways—EGFR—pancreatic cancer	4.3e-05	0.00036	CbGpPWpGaD
Latanoprost—SLC22A1—Metabolism—APOE—pancreatic cancer	4.18e-05	0.000349	CbGpPWpGaD
Latanoprost—PTGFR—Signaling Pathways—KRAS—pancreatic cancer	4.06e-05	0.00034	CbGpPWpGaD
Latanoprost—SLC22A1—Metabolism—PIK3CG—pancreatic cancer	3.77e-05	0.000315	CbGpPWpGaD
Latanoprost—PTGFR—Signaling Pathways—PIK3CA—pancreatic cancer	3.73e-05	0.000312	CbGpPWpGaD
Latanoprost—SLC22A1—Metabolism—PPARG—pancreatic cancer	3.64e-05	0.000304	CbGpPWpGaD
Latanoprost—PTGFR—Signaling Pathways—TP53—pancreatic cancer	3.61e-05	0.000302	CbGpPWpGaD
Latanoprost—PTGFR—Signaling Pathways—HRAS—pancreatic cancer	3.45e-05	0.000289	CbGpPWpGaD
Latanoprost—SLC22A1—Metabolism—PIK3CD—pancreatic cancer	3.31e-05	0.000277	CbGpPWpGaD
Latanoprost—PTGFR—Signaling Pathways—AKT1—pancreatic cancer	3.05e-05	0.000255	CbGpPWpGaD
Latanoprost—SLC22A1—Metabolism—PIK3CB—pancreatic cancer	2.89e-05	0.000242	CbGpPWpGaD
Latanoprost—SLC22A1—Metabolism—PTGS2—pancreatic cancer	2.86e-05	0.000239	CbGpPWpGaD
Latanoprost—SLC22A1—Metabolism—PTEN—pancreatic cancer	2.5e-05	0.000209	CbGpPWpGaD
Latanoprost—SLC22A1—Metabolism—PIK3CA—pancreatic cancer	1.76e-05	0.000147	CbGpPWpGaD
Latanoprost—SLC22A1—Metabolism—AKT1—pancreatic cancer	1.44e-05	0.00012	CbGpPWpGaD
